Zoom Logo

Biomedical Catalyst Early and Late Stage 2020 Briefing - Shared screen with speaker view
Rob Bevan
41:14
Many SMEs work with specialist OEMs for device manufacture, certified test centres for pre-clinical testing and CRO’s/specialist centres for clinical studies. These subcontracts can represent a significant proportion of early/late stage development costs (e.g. 50% - 70% of project costs). Is it viewed negatively if a significant proportion (e.g. >50%) of a partners or the projects costs lie in subcontracts? Assuming of course these are all justified and necessary for the project.
Rob Bevan
41:43
How is it viewed if a partners preferred subcontractor lies outside the UK? Is it OK to choose a non-UK subcontractor on the basis that they offer better value for money? For example, there might be a UK subcontractor that can offer the minimum quality of service required; however, a non-UK subcontractor might deliver a higher quality or additional offerings that add significant value to the project.
Rob Bevan
42:40
To achieve readiness for clinical studies, it is often necessary to transfer manufacture to pilot line. This can represent quite a significant cost. Are such activities eligible?